Video

Dr. Morris on the Promise of PSMA-Targeted PET Imaging in Prostate Cancer

Michael J. Morris, MD, discusses the promising future of prostate-specific membrane antigen–targeted PET imaging in prostate cancer.

Michael J. Morris, MD, medical oncologist, clinical director of Genitourinary Medical Oncology Service, and Prostate Cancer Section Head of the Division of Solid Tumor Oncology at Memorial Sloan Kettering Cancer Center, discusses the promising future of prostate-specific membrane antigen (PSMA)–targeted PET imaging in prostate cancer.

PSMA-targeted PET imaging has become one of the most promising molecular imaging modalities in prostate cancer, says Morris. Based on a multitude of data that continues to be collected on an international level, investigators now believe that PSMA-targeted PET imaging is superior to standard imaging modalities that are commonly used in the United States, such as cross-sectional anatomic imaging and skeletal scintigraphy, adds Morris.

However, to date, PSMA-targeted PET imaging has not yet received approval in the United States, says Morris. However, the phase 3 CONDOR study was designed to accumulate data for the regulatory approval of F-DCFPyL, a PSMA tracer.

CONDOR is 1 of 2 trials that is intended to provide the FDA with the necessary evidence needed to obtain regulatory approval of this agent for PSMA-targeted PET imaging in prostate cancer, concludes Morris.

Clinicians referring a patient to MSK can do so by visiting msk.org/refer, emailing [email protected], or by calling 833-315-2722.

Newsletter

Stay up to date on the most recent and practice-changing oncology data

Latest CME

View All
Tumor Board: Expert Insights on Managing Classical 𝘌𝘎𝘍𝘙 Mutations, 𝘌𝘎𝘍𝘙 Exon 20 Insertions, and Atypical 𝘌𝘎𝘍𝘙 Mutations in Metastatic NSCLC
Video

Tumor Board: Expert Insights on Managing Classical 𝘌𝘎𝘍𝘙 Mutations, 𝘌𝘎𝘍𝘙 Exon 20 Insertions, and Atypical 𝘌𝘎𝘍𝘙 Mutations in Metastatic NSCLC

Jun 6th 2025 - Jul 12th 2025

online-activity
Medical Crossfire®: Expert Perspectives on Targeting c-Met Overexpression and 𝘔𝘌𝘛 Genomic Alterations in NSCLC – Unveiling the Complexities of 𝘔𝘌𝘛 Dysregulation
Video

Medical Crossfire®: Expert Perspectives on Targeting c-Met Overexpression and 𝘔𝘌𝘛 Genomic Alterations in NSCLC – Unveiling the Complexities of 𝘔𝘌𝘛 Dysregulation

Jun 6th 2025 - Jul 12th 2025

online-activity
Evolving Treatment Strategies in Pancreatic Cancer: Current Standards, Emerging Targets, and the Role of Molecular Testing
Video

Evolving Treatment Strategies in Pancreatic Cancer: Current Standards, Emerging Targets, and the Role of Molecular Testing

Jun 5th 2025 - Jul 12th 2025

online-activity